HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?

AuthorsPier Paolo M Berton Giachetti, Giuseppe Curigliano
JournalNature reviews. Clinical oncology (Nat Rev Clin Oncol) Vol. 21 Issue 3 Pg. 171-172 (Mar 2024) ISSN: 1759-4782 [Electronic] England
PMID38114789 (Publication Type: Journal Article)
Chemical References
  • Trastuzumab
  • Docetaxel
  • pyrotinib
  • Acrylamides
  • Receptor, ErbB-2
  • Aminoquinolines
Topics
  • Humans
  • Female
  • Trastuzumab (therapeutic use)
  • Breast Neoplasms (drug therapy, genetics, pathology)
  • Docetaxel (therapeutic use)
  • Acrylamides (therapeutic use)
  • Receptor, ErbB-2 (genetics)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Aminoquinolines

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: